Reporting owner · CIK 0002034668

Hyep Ivan

Visual SEC Form 4 history across 1 companies, 4 transactions and 2 filings.

CFOChief Financial OfficerBicara Therapeutics Inc.
Open-market mix
Filings2Form 4 records
Buying$00 purchases
Selling$170.3K1 sales
Net value−$170.3KBuys minus sells
Companies12 securities
Most recentMar 23, 2026exercise

Latest insider transactions

Form 4 filings from available history. Click any column to sort; click it again to flip the order.

Hyep Ivan transactions
IDTickerInsiderRoleTypeSharesValueCodeFiledTrans date
#215898BCAXHyep Ivan
CFO
exercise10b5-19.19k$0M03/2403/23
#215897BCAXHyep Ivan
CFO
sale10b5-19.19k-$17.0MS03/2403/23
#215896BCAXHyep Ivan
CFO
exercise10b5-19.19k$3.48MM03/2403/23
#43596BCAXHyep Ivan
CFO
grant125k$0A02/0402/02

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at Bicara Therapeutics Inc. on Mar 23, 2026 valued at $170,348.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Latest sale

sale at Bicara Therapeutics Inc. on Mar 23, 2026 valued at $170,348.

Review SEC filing

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

2 observations · Mar 23, 2026 – Mar 23, 2026. Window ends at the latest available report, not today.

Selected observation · Mar 23, 2026145,355 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Mar 23, 2026154,555Mar 24, 2026View transaction
Mar 23, 2026145,355Mar 24, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
530-3-5Feb 261Mar 26

Net value flow

Buys minus sells

Feb 26
$0
Mar 26
−$170.3K

Transaction texture

Ownership and ticket size

Average P/S size$170.3K
Median P/S size$170.3K
Direct4
Indirect0
Mar 23, 2026exercise

Associated companies

Visual map of known reporting history

Hyep Ivan Insider Activity FAQ

SEC Form 4 context

Who is Hyep Ivan?

Hyep Ivan is a reporting owner in SEC Form 4 filings with reporting owner CIK 0002034668.

Which companies has Hyep Ivan reported transactions for?

Bicara Therapeutics Inc.

When was Hyep Ivan's latest insider buy?

No open-market insider purchase is available for this period.

When was Hyep Ivan's latest insider sale?

sale at Bicara Therapeutics Inc. on Mar 23, 2026 valued at $170,348.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.